Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy.

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy ...

A promising ALS drug may help combat glioblastoma by targeting the cancerous stem cells that fuel tumor growth.

Weiss highlighted a 2012 Cochrane Library review that examined research and found the drug is “reasonably safe” and prolongs ...

胶质母细胞瘤是侵袭性脑肿瘤，中位生存期仍不到22个月。FDA批准的ALS药物Edaravone能抑制iNOS信号，而iNOS信号是脑肿瘤干细胞的关键调节因子。基于此，加拿大研究人员发现Edaravone在临床前模型的治疗延迟了胶质母细胞瘤的发生，并延长临床前模型的寿命 ...

In an effort to rapidly identify new treatments effective against BTSCs, a team of researchers from the University of Ottawa, Canada, tested Edaravone, an FDA-approved drug, for its efficacy against ...

Research provides evidence that a drug used to slow the progression of the disease ALS shows promise in suppressing the self-renewing cancerous stem cells that challenge the present standards of care ...

Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It’s aggressive and incurable.